share_log

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $42

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $42

加拿大皇家银行资本维持Agios Pharmicals的表现跑赢大盘,将目标股价上调至42美元
Benzinga ·  2023/06/27 07:43

RBC Capital analyst Kennen MacKay maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and raises the price target from $40 to $42.

加拿大皇家银行资本分析师肯嫩·麦凯维持Agios Pharmicals(纳斯达克股票代码:AGIO)的表现跑赢大盘,并将目标股价从40美元上调至42美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发